Phase I trial comparing the bioavailability of three abuse-deterrent levophanol extended-release formulations with the immediate release formulation.
Latest Information Update: 16 Sep 2013
Price :
$35 *
At a glance
- Drugs Levorphanol (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 10 Sep 2013 Results published in a Relmada Therapeutics Media Release.
- 01 Sep 2013 Status changed from not yet recruiting to completed.
- 06 Mar 2013 New trial record